Format

Send to

Choose Destination
Nanomedicine. 2015 Jul;11(5):1109-15. doi: 10.1016/j.nano.2015.02.015. Epub 2015 Mar 16.

A novel topical nano-propranolol for treatment of infantile hemangiomas.

Author information

1
Department of Oromaxillofacial Head and Neck Oncology, Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Department of Oral and Maxillofacial Surgery, Qingdao Municipal Hospital, Shandong, China.
2
Department of Oromaxillofacial Head and Neck Oncology, Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: davidzhengjw@sjtu.edu.cn.
3
School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
4
Department of Oromaxillofacial Head and Neck Oncology, Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
5
School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China. Electronic address: yuanweien@126.com.

Abstract

Topical propranolol has been used for the therapy of superficial infantile hemangiomas (IH). A retrospective investigation was conducted in 50 patients to evaluate the clinical effect of a new type of topical nano-propranolol-dispersed hydrogel. Participants were treated 3 times per day for 2 weeks to 11 months. 68% of patients were female and 12% had received other treatments before therapy. The nano-propranolol 0.5% hydrogel was initiated at a mean age of 5.010 months and for a mean duration of 3.610 months. The response rate was 86%. No recurrence and rebound growth occurred after withdrawal of hydrogel. Slight side effects (application site itching, erosion and crusting) were observed in only 2 cases. All the local irritations were evaluated as mild and were tolerated without discontinuing the medication. We suggest that topical nano-propranolol hydrogel could be an alternative option for the treatment of uncomplicated superficial IH with satisfactory tolerability and optimal effectiveness.

FROM THE CLINICAL EDITOR:

The current recommended treatment for infantile hemangiomas is oral propranolol. Nonetheless, a small proportion of patients will have systemic side effects. In this article, the authors developed topical nano-propranolol hydrogel and tested this on clinical patients and found favorable response.

KEYWORDS:

Beta blocker; Infantile hemangioma; Propranolol; Topical therapy

PMID:
25791814
DOI:
10.1016/j.nano.2015.02.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center